Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that the isotope-dilution GC-MS technique can assess 5α-reductase activity more effectively than conventional methods in rat liver S9 fractions, particularly at low testosterone levels.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

This study found that in sleep-deprived rats, increased 5α-reductase expression and activity in the prefrontal cortex contributed to psychosis- and mania-like symptoms, which finasteride ameliorated in a dose-dependent manner.

This study found that AR-007 degrades faster and has a stronger association with hsp70 than AR-014, suggesting it is less stable when bound to the androgen receptor.

This study found that in men with sexual dysfunction, use of 5ARI may reduce sexual drive and spontaneous erections without worsening pre-existing erectile or ejaculatory issues.

This study synthesized nonsteroidal ligands as second-generation androgen receptor agonists and identified three compounds with significant anabolic activity and moderate to minimal androgenic activity in vivo.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This study found that inhibiting the 5alpha-reductase 2 pathway in male rats affects brain sexual differentiation and leads to reproductive changes, including increased pre-implantation loss despite unchanged copulatory potential.

This article discusses the functions of the enzyme 17beta-HSD10, including its role in steroid metabolism and potential links to Alzheimer's disease, but reports no new experimental findings.

This study by Gao et al. reports that two nonsteroidal selective androgen receptor modulators, S1 and S4, demonstrated tissue-selective actions in rats, suppressing prostate growth while maintaining muscle growth without altering hormone levels.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

This study concluded that administering 5-alpha reductase inhibitors before photoselective vaporization of the prostate increased hemoglobin change, lasing time, and energy required during the procedure compared to controls.

Isolation stress in rats reduces brain enzyme levels, affecting dopamine function.

This article describes the use, action, and considerations for 5-alpha-reductase inhibitors in treating benign prostatic hyperplasia and androgenic alopecia but provides no new clinical results, emphasizing existing knowledge and guidelines for healthcare providers.

This study found that male 5αR1 knockout mice and obese Zucker rats treated with finasteride showed increased insulin resistance and hepatic steatosis, potentially implicating 5α-reductase activity in metabolic liver disease development.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This study suggests that 5-ADIOL-S may contribute to the synthesis of potent androgens in peripheral tissues, and 3 alpha-DIOL-S could be a marker of androgen metabolism in various female patient groups.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study found that acute sleep deprivation enhanced 5α-reductase expression and activity in the rat prefrontal cortex, and finasteride treatment reduced associated psychosis- and mania-like behaviors.

This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

This study found no significant genetic association between the 5α-reductase enzyme genes and male pattern baldness, suggesting a polygenic etiology rather than simple inheritance.